{"@context":{"@vocab":"https://schema.org/"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/fda/warning-letters/check?name=Purushothaman%20Damodara%20Kumaran%2C%20M.D.","name":"Purushothaman Damodara Kumaran, M.D.","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://creativecommons.org/publicdomain/zero/1.0/","primary_source":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters","generated_at":"2026-10-06T03:02:58.075Z"},"count":1,"matches":[{"id":"84c27e9c18466c57","posted_date":"2026-01-13","letter_issue_date":"2025-12-22","company_name":"Purushothaman Damodara Kumaran, M.D.","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"In Vivo Bioavailability-Bioequivalence Studies – Clinical","canonical_url":"https://api.morvs.ai/fda-warning/84c27e9c18466c57"}]}